Source Feed: The Globe and Mail
Author: Danielle Groen
Publication Date: October 7, 2025 - 06:10
Morning Update: Trump’s plan for ‘eternal peace’ in the Middle East
October 7, 2025
Good morning. Israel and Hamas are back at the negotiating table, hashing out the thorniest issues in the U.S. peace plan – more on that below, along with another high-profile resignation in France and the Blue Jays’ quest for a series sweep. But first:
Today’s headlines- Ahead of talks with Carney, Trump says his tariffs are working
- Alberta’s teachers’ strike begins, affecting around 700,000 students
- Ontario to offer early access to some new cancer drugs in pilot project
Unpublished Newswire
Doctors are calling on provinces to bolster addiction treatment services in response to growing opioid use among young people, a crisis they fear will escalate for decades to come if immediate action is not taken.In a Canadian Medical Association Journal (CMAJ) editorial published Monday, physicians Shannon Charlebois and Shawn Kelly say the escalation of opioid use among youth is being overlooked. Existing addiction services, they say, are also inadequate to meet the needs of young people with opioid use disorder, or OUD.
October 27, 2025 - 00:01 | Alanna Smith | The Globe and Mail
The Alberta government is expected to introduce back-to-work legislation on Monday to force striking teachers to return to classrooms after three weeks, raising fears among labour advocates that the province will invoke the Charter’s notwithstanding clause to override workers’ rights. More than 750,000 students have been out of class since Oct. 6, after negotiations between the Alberta Teachers’ Association and the province broke down.
October 26, 2025 - 21:24 | Meera Raman | The Globe and Mail
Health Canada has for the first time approved a disease-modifying drug for Alzheimer’s disease, a watershed moment that offers hope for patients but does not guarantee that the complex and expensive intravenous therapy will be widely available in this country. The federal regulator on Friday granted a conditional authorization for lecanemab, an antibody drug that can slow the progression of the disease for some people with mild cognitive impairment or early-stage dementia owing to Alzheimer’s.
October 26, 2025 - 21:08 | Kelly Grant | The Globe and Mail
Comments
Be the first to comment